By The Survivors Club Staff
June 25, 2009
A new drug treatment for cancer has produced "highly promising results" in preliminary trials, according to new research published in the prestigious New England Journal of Medicine.
The new cancer drug, called Olaparib, was given to 19 patients with inherited forms of advanced breast cancer, ovarian cancer and prostate cancer caused by mutations of the BRCA1 and BRCA2 genes. With 12 patients - among whom other treatments had failed - cancer tumors shrank or stabilized. In one case, a woman with breast cancer is still in remission two years after being one of the first to be treated with Olaparib.
Olaparib is a member of a new class of drugs called PARP inhibitors that target cancer cells but leave healthy cells relatively untouched. NBC's science correspondent Robert Bazell calls this news "the most exciting development in
Survivors In The News

